Logo

TBPH

Theravance Biopharma, Inc.

TBPH

Theravance Biopharma, Inc. • NASDAQ
$20.30 ▲ 1.70% (+0.34)
Market Cap $1.03 B
52w High $20.33
52w Low $7.90
Dividend Yield 0%
P/E 35.61
Volume 387.46K
Outstanding Shares 50.67M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $19.99M ▼ $18.333M ▼ $3.615M ▼ 18.084% ▼ $0.07 ▼ $-1.907M ▲
Q2-2025 $26.195M ▲ $18.43M ▲ $54.835M ▲ 209.334% ▲ $1.09 ▲ $-2.316M ▲
Q1-2025 $15.388M ▼ $18.37M ▼ $-13.579M ▲ -88.244% ▼ $-0.27 ▲ $-14.021M ▼
Q4-2024 $18.754M ▲ $27.954M ▲ $-15.527M ▼ -82.793% ▼ $-0.31 ▼ $-7.601M ▲
Q3-2024 $16.868M $18.437M $-12.698M -75.279% $-0.26 $-8.846M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $329.68M ▼ $415.46M ▼ $182.779M ▼ $232.681M ▲
Q2-2025 $338.804M ▲ $426.035M ▲ $201.187M ▲ $224.848M ▲
Q1-2025 $130.855M ▲ $343.582M ▼ $177.599M ▼ $165.983M ▼
Q4-2024 $88.35M ▼ $354.161M ▼ $178.616M ▲ $175.545M ▼
Q3-2024 $91.361M $356.105M $170.451M $185.654M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $3.615M ▼ $-6.508M ▼ $-100.246M ▼ $-400K ▲ $-107.154M ▼ $-6.508M ▼
Q2-2025 $54.835M ▲ $208.074M ▲ $-36.258M ▼ $-503K ▲ $171.313M ▲ $208.04M ▲
Q1-2025 $-13.579M ▲ $43.039M ▲ $30.632M ▲ $-854K ▼ $72.817M ▲ $43.039M ▲
Q4-2024 $-15.527M ▼ $-902K ▲ $15.686M ▲ $-365K ▲ $14.419M ▲ $-1.092M ▲
Q3-2024 $-12.698M $-5.196M $-17.399M $-372K $-22.967M $-5.211M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Collaborative Arrangement Revenue
Collaborative Arrangement Revenue
 $0 ▲$0 ▲$20.00M ▲$20.00M ▲
License
License
 $0 ▲$0 ▲$10.00M ▲$10.00M ▲
YUPELRI Monotherapy
YUPELRI Monotherapy
 $20.00M ▲$20.00M ▲$20.00M ▲$0 ▼
Collaboration revenue
Collaboration revenue
 $0 ▲$20.00M ▲$0 ▼$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Theravance’s income statement still reflects a classic development‑stage biotech profile: very modest revenue and ongoing losses. The positive side is that losses have been shrinking over the past few years as the company has cut costs and narrowed its focus. Profitability is not yet in sight, but the direction of travel is better than it was around 2020–2021, when losses were much heavier. Revenue depends heavily on a small set of respiratory assets, so the top line is relatively flat and fragile, while the improvement mainly comes from tighter spending rather than strong growth.

Balance Sheet

Balance Sheet The balance sheet has improved meaningfully from the days when equity was negative and debt was heavy. Today, the company carries far less leverage and has rebuilt positive equity, which gives it more financial flexibility than a few years ago. That said, total assets have come down from prior peaks, and the cash cushion is much smaller than it once was, so there is less room for prolonged cash burn without some form of replenishment over time. Overall, it looks cleaner and less risky than before, but not yet comfortably robust for the long term if losses persist.

Cash Flow

Cash Flow Cash flows are still negative, meaning the business is consuming cash rather than generating it. Operating cash outflows have been narrowing, helped by lower R&D and operating costs after the strategic restructuring. Capital spending is very light, so almost all of the cash movement reflects core operations rather than big investments in physical assets. The burn rate appears more controlled than in earlier years, but the company still relies on its existing cash and any external funding or partnership income to support ongoing development and commercialization efforts.

Competitive Edge

Competitive Edge Theravance competes in focused, niche areas rather than broad crowded markets. Its main commercial product, YUPELRI, occupies a unique slot as the only once‑daily nebulized maintenance therapy in its part of the COPD market, supported by a commercial partner with strong respiratory experience. This gives it a defensible, if narrow, competitive space. On the pipeline side, ampreloxetine targets a rare neurological condition with few good options, where orphan status and a first‑in‑class profile could provide meaningful differentiation if late‑stage data are successful. The flip side is concentration risk: the company’s prospects lean heavily on just one commercial product and one key late‑stage asset, making outcomes very sensitive to competitive and clinical developments.

Innovation and R&D

Innovation and R&D Innovation is centered on the idea of “organ‑selective” medicines, especially inhaled therapies for lung diseases and targeted drugs for neurological conditions. The company has a track record in respiratory science, exemplified by YUPELRI and past collaborations, and has deliberately trimmed its pipeline to focus resources on what it views as its best opportunities. R&D is now concentrated on advancing ampreloxetine through a pivotal trial and on selectively nurturing a smaller set of follow‑on programs, such as inhaled anti‑inflammatory approaches. This focused strategy can make R&D spending more efficient, but it also means fewer backup programs if lead assets disappoint, so clinical execution and trial results are especially critical.

Summary

Theravance Biopharma today is a leaner, more focused biotech than it was a few years ago. Financially, it remains loss‑making with ongoing cash burn, but losses are smaller and the balance sheet is cleaner, with much less debt and restored positive equity. The business model currently rests on a modest but strategically important respiratory franchise and a high‑stakes late‑stage neurology program. Its scientific edge lies in organ‑selective drug design and deep respiratory expertise, which support a narrow but defensible competitive niche. Looking forward, the company’s trajectory will be driven largely by: continued commercial traction for YUPELRI, the outcome of the pivotal trial for ampreloxetine, and its ability to manage cash carefully while pursuing these opportunities in a concentrated portfolio.

NEWS

November 20, 2025 · 11:00 AM UTC

Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

Read more

November 19, 2025 · 6:00 AM UTC

Theravance Biopharma to Participate in Upcoming Investor Conferences

Read more

November 10, 2025 · 4:05 PM UTC

Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Read more

October 29, 2025 · 6:00 AM UTC

Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System

Read more

October 27, 2025 · 6:00 AM UTC

Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025

Read more